Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex

Hisato Maekawa, Hiroaki Sato, Douglas M. Tollefsen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The rate of thrombin inhibition by heparin cofactor II (HCII) is facilitated by heparin or dermatan sulfate in vitro. The distributions of these glycosaminoglycans (GAGs) in vivo are not the same; heparin-like substance is rich on the surface of endothelial cells and dermatan sulfate is relatively dominant in the extravascular region. When inflammation takes place, at least two other possible existent forms of HCII, the complexed form with thrombin and the cleaved form by leukocyte elastase, are assumed to be present at relatively high concentrations in a local circumstance. We examined the interactions of HCII with the two forms of HCII on thrombin inhibition in the presence of the GAGs. By HCII in complex with thrombin or cleaved by leukocyte elastase, the affinity of HCII moiety for heparin increases and that for dermatan sulfate decreases. The two forms possibly occur at relatively high concentrations in a local pathological situation, although the heparin cofactor activity for thrombin inhibition by HCII decreases and dermatan sulfate determines the cofactor activity. These results indicate efficient thrombin inhibitory activity of HCII in the extravascular region.

Original languageEnglish
Pages (from-to)443-451
Number of pages9
JournalThrombosis Research
Volume100
Issue number5
DOIs
StatePublished - Dec 1 2000

Keywords

  • Dermatan sulfate
  • Heparin
  • Heparin cofactor II
  • Leukocyte elastase
  • Thrombin

Fingerprint Dive into the research topics of 'Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex'. Together they form a unique fingerprint.

Cite this